Sign In
Buy CPIX
$6.54
+0.610 (+10.29%)
At Close: Jul 13, 2026
/C O R R E C T I O N -- Cumberland Pharmaceuticals Inc./
12:00pm, Monday, 13'th Jul 2026
/C O R R E C T I O N -- Cumberland Pharmaceuticals Inc./ PR Newswire NASHVILLE, Tenn., July 13, 2026
CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE
11:00am, Monday, 13'th Jul 2026
CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE PR Newswire NASHVILLE, Tenn., July 13,
CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE
10:46am, Monday, 13'th Jul 2026
Record Date is July 10, 2026 & Payment Date is July 31,2026 Corporate and Insider Share Purchase Initiatives to Continue NASHVILLE, Tenn., July 13, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.
Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals
09:00am, Wednesday, 01'st Jul 2026
TORONTO, July 1, 2026 /PRNewswire/ - Apotex Health Corp. ("Apotex") (TSX: APTX), the largest Canadian-based pharmaceutical company, today announced the closing of its previously announced strategic tr
Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex
09:00am, Wednesday, 01'st Jul 2026
$100 million Transaction Follows Cumberland Shareholder Approval Strengthens Cumberland's Focus on Rare Disease Pipeline NASHVILLE, Tenn., July 1, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
12:00pm, Friday, 26'th Jun 2026
Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference PR
Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
11:00am, Friday, 26'th Jun 2026
Additional cardiac biomarker analyses further demonstrate ifetroban's cardioprotective effect in DMD patients NASHVILLE, Tenn., June 26, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: C
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
04:10pm, Monday, 22'nd Jun 2026
$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel and RALEIGH, N.C., June 22, 2026 /PRNewswire/ --
RedHill Biopharma Announces Up To $19.4 Million Private Placement
08:00am, Thursday, 18'th Jun 2026
$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel & RALEIGH, N.C., June 18, 2026 /PRNewswire/ -- R
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
07:00am, Tuesday, 09'th Jun 2026
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most commonly affecting babies and young
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
07:00am, Monday, 08'th Jun 2026
RALEIGH, N.C. and TEL-AVIV, Israel, June 8, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.
Cumberland's Ifetroban Shows Potential to Limit Metastasis
10:06am, Thursday, 04'th Jun 2026
CPIX reports positive Phase 2a results for Ifetroban, showing a favorable safety profile and promising early signs of reducing cancer metastasis in high-risk patients.
Cumberland Expands Global Reach With Vibativ Launch in China
10:11am, Tuesday, 02'nd Jun 2026
CPIX launches Vibativ in China through SciClone, expanding access to its antibiotic treatment for serious Gram-positive bacterial infections.
Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis
09:05am, Tuesday, 02'nd Jun 2026
Positive Results from Phase 2a Clinical Trial Study met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumors Trial revealed promising effica
Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively d
